Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies

Gautam Borthakur, Yesid Alvarado, Farhad Ravandi-Kashani, Jorge Cortes, Zeev Estrov, Stefan Faderl, Percy Ivy, Carlos Bueso-Ramos, B. Nebiyou Bekele, Francis Giles

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences